Compound class:
Synthetic organic
Comment: Compound 38k is a potent inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3) [1]. It is proposed as a novel therapeutic agent for the treatment of metastatic breast cancer. Compound 38k suppresses the VEGFR3 signalling pathway, bringing about apoptosis in target cells.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 38k inhibits proliferation and migration of VEGF-C-induced breast cancer cells in vitro, and is orally active in a breast cancer xenograft model [1]. The IC50s for 38k inhibition of VEGFR1 and VEGFR2 are >10μM in vitro. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|